Tysabri FDA Approval History
FDA Approved: Yes (First approved November 23, 2004)
Brand name: Tysabri
Generic name: natalizumab
Dosage form: Injection
Previous Name: Antegren
Company: Biogen Idec / Elan Corporation, plc
Treatment for: Multiple Sclerosis, Crohn's Disease, Maintenance
Tysabri (natalizumab) is a recombinant humanized IgG4κ monoclonal antibody for the treatment of multiple sclerosis and Crohn's disease.
Development Timeline for Tysabri
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.